Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models

MLA

Deepak Sampath, et al. Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Apr. 2023. EBSCOhost, https://doi.org/10.1158/1535-7163.22507863.

APA

Deepak Sampath, Andrew J. Souers, Martine Amiot, Wayne J. Fairbrother, Sophie Maiga, Leslie Lee, Jason Oeh, Peng Yue, Paul Tapang, Anatol Oleksijew, Walter C. Darbonne, Ellen Ingalla, Michael Mitten, Amy Young, Nguyen Tan, Lisa D. Belmont, Erwin R. Boghaert, Franklin Peale, Joel D. Leverson, & Elizabeth A. Punnoose. (2023). Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. https://doi.org/10.1158/1535-7163.22507863

Chicago

Deepak Sampath, Andrew J. Souers, Martine Amiot, Wayne J. Fairbrother, Sophie Maiga, Leslie Lee, Jason Oeh, et al. 2023. “Supplementary Table 2 from Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models,” April. doi:10.1158/1535-7163.22507863.